A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options (CPCT-03)
Overview
- Phase
- N/A
- Intervention
- Everolimus
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Sponsor
- UMC Utrecht
- Enrollment
- 73
- Locations
- 3
- Primary Endpoint
- analyse a set of 1951 genes for prediction of response measured by time to progression (TTP) ratio (defined as the TTP without drug: TTP on drug) on mTOR inhibition.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The investigators hypothesize that certain mutations in the individual cancer genomes will predict response to Everolimus therapy. To identify possible genetic mutations that affect tumor response to Everolimus the investigators will obtain sequence analysis of tumors from all patients that will be treated with Everolimus in this study. Moreover, the investigators performed a systematic review of the currently available data to identify mutations that could be predictive for increased mTOR activity in cancer cells. These mutations have been described to lead to mTOR activation but their predictive value for response to Everolimus therapy remains unclear. The investigators will use the data generated in the investigators own prospective treatment study and the data from literature to select patients for entry into a second part of this trial. In this part the investigators want to test the hypothesis that selecting patients based on their specific genetic mutations increases the likelihood of response.
Investigators
P.O. Witteveen
Investigator
UMC Utrecht
Eligibility Criteria
Inclusion Criteria
- •Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up
- •Inclusion in the CPCT-02 study
- •Age ≥ 18 years
- •Diagnosis of malignant tumor showing progressive disease according to investigators opinion
- •WHO performance status of (0-2)
- •Measurable disease allowing for volumetric measurements
- •No availability of standard of care systemic treatment options or patient refuses to receive standard of care chemotherapy treatment
- •A female is eligible to enter and participate in this study if she is of: Non-childbearing potential
- •Adequate organ system function as defined in the protocol
- •Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5 × ULN.
Exclusion Criteria
- •Previous treatment with mTOR inhibitors/pi3k inhibitors/AKT inhibitors
- •Uncontrolled hypertension defined as RR \> 160/95 mmHg
- •Serious non-healing wound, ulcer or bone fracture
- •Within 7 days of surgery (including minor procedures)
- •Known and/or symptomatic intracerebral metastases
- •Pregnancy or breast feeding, reproductive potential not using effective birth control methods
- •Severe medical condition(s) prohibiting participation in the study
- •Use of other investigational agents now or last 28 days prior to study treatment start
- •Unable or unwilling to discontinue use of interacting medications or modify the dosing of interacting drugs for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study
- •Less than four weeks after regular treatment/ palliative radiotherapy
Arms & Interventions
everolimus
All patients in first part will receive everolimus 10mg q.d.
Intervention: Everolimus
Outcomes
Primary Outcomes
analyse a set of 1951 genes for prediction of response measured by time to progression (TTP) ratio (defined as the TTP without drug: TTP on drug) on mTOR inhibition.
Time Frame: An expected average of 5 months
Inclusion until earliest date of disease progression (defined as a 30% volumetric increase in tumorvolume or appearance of new lesions)
Secondary Outcomes
- Disease control rate (DCR)(At 3 months after initiation of everolimus)
- Progression free survival(An expected average of 4 months)
- Toxicity(An expected average of 6 months)
- Median overall survival(An expected average of one year)